Overview

Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether HPN-100 is safe and tolerable in subjects with Urea Cycle Disorders.
Phase:
Phase 2
Details
Lead Sponsor:
Horizon Pharma Ireland, Ltd., Dublin Ireland
Treatments:
4-phenylbutyric acid
Glycerol